ALX Oncology Q1 2026 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 51 minutes ago
0mins
Should l Buy ALXO?
Source: seekingalpha
- Clinical Data Highlights: At the ESMO Breast 2026 conference in Munich, ALX Oncology reported that all confirmed HER2-positive and CD47 high-expressing patients achieved a response, including one complete response, indicating that CD47 expression is a key predictive biomarker for enhancing durable clinical responses.
- Market Opportunity Assessment: The company estimates approximately 20,000 HER2-positive and CD47-overexpressing patients in the U.S. and five major European markets and Japan, representing a market opportunity of $2 billion to $4 billion, showcasing the potential commercial value of its products.
- Trial Progress Update: ALX Oncology is advancing the ASPEN-09 study, aiming to enroll up to 120 patients with a primary endpoint of response rate in CD47-overexpressing patients, with initial data from approximately 80 patients expected by mid-2027, further validating its treatment strategy.
- Leadership Enhancement: The company appointed Jeff Knight as Chief Development and Chief Operating Officer, further strengthening the leadership team to ensure the smooth progress of clinical trials and the implementation of the overall corporate strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALXO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALXO
Wall Street analysts forecast ALXO stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.870
Low
2.00
Averages
3.33
High
4.00
Current: 1.870
Low
2.00
Averages
3.33
High
4.00
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ALX Oncology Q1 Earnings Beat Expectations
- Earnings Performance: ALX Oncology reported a Q1 GAAP EPS of -$0.17, beating expectations by $0.02, indicating some improvement in financial management that may boost investor confidence.
- Cash Reserves: As of March 31, 2026, the company had $169.1 million in cash, cash equivalents, and investments, sufficient to fund operations through the first half of 2028, reflecting strong liquidity management.
- Clinical Trial Readiness: ALX Oncology aims to complete pivotal trial readiness by the end of 2026 with an expanded ASPEN-09 study, showcasing proactive advancements in R&D that could lay the groundwork for future product launches.
- Financing Plans: The company is pursuing $150 million in financing to support its clinical trials and operations, demonstrating ALX Oncology's confidence in future growth and strategic positioning in the market.
See More
ALX Oncology Presents Promising Evorpacept Data at ESMO Breast Cancer 2026
- Clinical Trial Results: At the 2026 ESMO Congress, ALX Oncology presented data showing that all patients with high CD47 expression receiving evorpacept in combination with zanidatamab experienced durable responses, reinforcing the CD47-selection hypothesis and potentially derisking the path forward in HER2-positive breast cancer.
- Trial Progress: The ongoing Phase 2 ASPEN-09-Breast trial is on track to provide topline data for 80 patients in mid-2027, combining trastuzumab and chemotherapy, aimed at offering new treatment options for HER2-positive patients and addressing the urgent market need for novel therapies.
- Leadership Enhancement: ALX Oncology appointed Jeff Knight as Chief Development and Operating Officer, leveraging over 30 years of experience in the biopharmaceutical industry to strengthen the company's development capabilities and operational infrastructure to support upcoming milestones.
- Improved Financial Position: As of March 31, 2026, ALX reported cash and cash equivalents of $169.1 million, which is expected to fund operations through the first half of 2028, demonstrating the company's financial stability as it advances its clinical programs.
See More
ALX Oncology Q1 2026 Earnings Call Insights
- Clinical Data Highlights: At the ESMO Breast 2026 conference in Munich, ALX Oncology reported that all confirmed HER2-positive and CD47 high-expressing patients achieved a response, including one complete response, indicating that CD47 expression is a key predictive biomarker for enhancing durable clinical responses.
- Market Opportunity Assessment: The company estimates approximately 20,000 HER2-positive and CD47-overexpressing patients in the U.S. and five major European markets and Japan, representing a market opportunity of $2 billion to $4 billion, showcasing the potential commercial value of its products.
- Trial Progress Update: ALX Oncology is advancing the ASPEN-09 study, aiming to enroll up to 120 patients with a primary endpoint of response rate in CD47-overexpressing patients, with initial data from approximately 80 patients expected by mid-2027, further validating its treatment strategy.
- Leadership Enhancement: The company appointed Jeff Knight as Chief Development and Chief Operating Officer, further strengthening the leadership team to ensure the smooth progress of clinical trials and the implementation of the overall corporate strategy.
See More
ALX Oncology Grants Stock Options to New COO
- Stock Option Grant: On April 16, 2026, ALX Oncology granted 800,000 stock options to new COO Jeff Knight at an exercise price of $1.68 per share, aligning with Nasdaq rules to incentivize his employment and drive business growth.
- Vesting Schedule: The stock options vest 25% on the one-year anniversary of April 13, 2026, with the remainder vesting monthly, ensuring Knight's continued service and motivation within the company.
- Pipeline Advancement: ALX Oncology is advancing its cancer treatment pipeline, with lead candidate Evorpacept showing potential as a cornerstone therapy in immuno-oncology, currently evaluated in multiple clinical trials, which is expected to positively impact future growth.
- New Drug Development: The second candidate, ALX2004, is undergoing a Phase 1 dose-escalation trial for EGFR-expressing solid tumors, and successful outcomes could further enrich the company's product line and enhance market competitiveness.
See More
ALX Oncology Appoints New Chief Development Officer
- Executive Appointment: ALX Oncology appointed Jeff Knight as Chief Development and Operating Officer effective April 13, 2026, bringing over 30 years of biopharmaceutical experience, previously at Crinetics Pharmaceuticals, where he oversaw clinical development and corporate operations, expected to drive success in clinical projects.
- Clinical Program Outlook: The evorpacept and ALX2004 clinical programs are anticipated to serve as significant catalysts in the next 12 to 18 months, with Knight's leadership expected to enhance the company's development capabilities and operational infrastructure, ensuring high-quality execution and achievement of upcoming milestones.
- Industry Expertise: Knight has held senior leadership roles at renowned biopharmaceutical companies, including Amgen and Genentech, where he gained extensive experience in oncology clinical development and regulatory affairs, providing robust support for ALX Oncology's strategic growth.
- Company Vision: Knight expressed that ALX Oncology is entering a critical growth phase with multiple opportunities to advance its pipeline, and he is excited about the company's clinical programs and data, looking forward to collaborating with the team to ensure strategic development and operational excellence.
See More
ALX Oncology Q4 2025 Earnings Call Highlights
- Executive Appointment: ALX Oncology announced the appointment of Dr. Barbara Klencke as Chief Medical Officer, succeeding her interim role since September 2025, with management highlighting the importance of this appointment during a critical inflection point for the company.
- Clinical Progress: The company reported significant advancements in the clinical development of evorpacept and ALX2004, having treated over 750 patients, with plans to advance these programs to pivotal study readiness by the end of next year, demonstrating strong execution and stable timelines.
- Successful Financing: ALX Oncology completed a $150 million financing round, strengthening its balance sheet and enabling the company to deliver more meaningful data in its ongoing clinical programs, with expectations to support operations through the first half of 2028.
- Financial Performance: The company reported a GAAP net loss of $22.8 million for Q4 2025, or $0.42 per share, a decrease from $29.2 million in the prior year period, reflecting reduced spending following pipeline prioritization efforts.
See More
ALX Oncology Q1 Earnings Beat Expectations
- Earnings Performance: ALX Oncology reported a Q1 GAAP EPS of -$0.17, beating expectations by $0.02, indicating some improvement in financial management that may boost investor confidence.
- Cash Reserves: As of March 31, 2026, the company had $169.1 million in cash, cash equivalents, and investments, sufficient to fund operations through the first half of 2028, reflecting strong liquidity management.
- Clinical Trial Readiness: ALX Oncology aims to complete pivotal trial readiness by the end of 2026 with an expanded ASPEN-09 study, showcasing proactive advancements in R&D that could lay the groundwork for future product launches.
- Financing Plans: The company is pursuing $150 million in financing to support its clinical trials and operations, demonstrating ALX Oncology's confidence in future growth and strategic positioning in the market.
See More
ALX Oncology Presents Promising Evorpacept Data at ESMO Breast Cancer 2026
- Clinical Trial Results: At the 2026 ESMO Congress, ALX Oncology presented data showing that all patients with high CD47 expression receiving evorpacept in combination with zanidatamab experienced durable responses, reinforcing the CD47-selection hypothesis and potentially derisking the path forward in HER2-positive breast cancer.
- Trial Progress: The ongoing Phase 2 ASPEN-09-Breast trial is on track to provide topline data for 80 patients in mid-2027, combining trastuzumab and chemotherapy, aimed at offering new treatment options for HER2-positive patients and addressing the urgent market need for novel therapies.
- Leadership Enhancement: ALX Oncology appointed Jeff Knight as Chief Development and Operating Officer, leveraging over 30 years of experience in the biopharmaceutical industry to strengthen the company's development capabilities and operational infrastructure to support upcoming milestones.
- Improved Financial Position: As of March 31, 2026, ALX reported cash and cash equivalents of $169.1 million, which is expected to fund operations through the first half of 2028, demonstrating the company's financial stability as it advances its clinical programs.
See More
ALX Oncology Q1 2026 Earnings Call Insights
- Clinical Data Highlights: At the ESMO Breast 2026 conference in Munich, ALX Oncology reported that all confirmed HER2-positive and CD47 high-expressing patients achieved a response, including one complete response, indicating that CD47 expression is a key predictive biomarker for enhancing durable clinical responses.
- Market Opportunity Assessment: The company estimates approximately 20,000 HER2-positive and CD47-overexpressing patients in the U.S. and five major European markets and Japan, representing a market opportunity of $2 billion to $4 billion, showcasing the potential commercial value of its products.
- Trial Progress Update: ALX Oncology is advancing the ASPEN-09 study, aiming to enroll up to 120 patients with a primary endpoint of response rate in CD47-overexpressing patients, with initial data from approximately 80 patients expected by mid-2027, further validating its treatment strategy.
- Leadership Enhancement: The company appointed Jeff Knight as Chief Development and Chief Operating Officer, further strengthening the leadership team to ensure the smooth progress of clinical trials and the implementation of the overall corporate strategy.
See More
ALX Oncology Grants Stock Options to New COO
- Stock Option Grant: On April 16, 2026, ALX Oncology granted 800,000 stock options to new COO Jeff Knight at an exercise price of $1.68 per share, aligning with Nasdaq rules to incentivize his employment and drive business growth.
- Vesting Schedule: The stock options vest 25% on the one-year anniversary of April 13, 2026, with the remainder vesting monthly, ensuring Knight's continued service and motivation within the company.
- Pipeline Advancement: ALX Oncology is advancing its cancer treatment pipeline, with lead candidate Evorpacept showing potential as a cornerstone therapy in immuno-oncology, currently evaluated in multiple clinical trials, which is expected to positively impact future growth.
- New Drug Development: The second candidate, ALX2004, is undergoing a Phase 1 dose-escalation trial for EGFR-expressing solid tumors, and successful outcomes could further enrich the company's product line and enhance market competitiveness.
See More
ALX Oncology Appoints New Chief Development Officer
- Executive Appointment: ALX Oncology appointed Jeff Knight as Chief Development and Operating Officer effective April 13, 2026, bringing over 30 years of biopharmaceutical experience, previously at Crinetics Pharmaceuticals, where he oversaw clinical development and corporate operations, expected to drive success in clinical projects.
- Clinical Program Outlook: The evorpacept and ALX2004 clinical programs are anticipated to serve as significant catalysts in the next 12 to 18 months, with Knight's leadership expected to enhance the company's development capabilities and operational infrastructure, ensuring high-quality execution and achievement of upcoming milestones.
- Industry Expertise: Knight has held senior leadership roles at renowned biopharmaceutical companies, including Amgen and Genentech, where he gained extensive experience in oncology clinical development and regulatory affairs, providing robust support for ALX Oncology's strategic growth.
- Company Vision: Knight expressed that ALX Oncology is entering a critical growth phase with multiple opportunities to advance its pipeline, and he is excited about the company's clinical programs and data, looking forward to collaborating with the team to ensure strategic development and operational excellence.
See More
ALX Oncology Q4 2025 Earnings Call Highlights
- Executive Appointment: ALX Oncology announced the appointment of Dr. Barbara Klencke as Chief Medical Officer, succeeding her interim role since September 2025, with management highlighting the importance of this appointment during a critical inflection point for the company.
- Clinical Progress: The company reported significant advancements in the clinical development of evorpacept and ALX2004, having treated over 750 patients, with plans to advance these programs to pivotal study readiness by the end of next year, demonstrating strong execution and stable timelines.
- Successful Financing: ALX Oncology completed a $150 million financing round, strengthening its balance sheet and enabling the company to deliver more meaningful data in its ongoing clinical programs, with expectations to support operations through the first half of 2028.
- Financial Performance: The company reported a GAAP net loss of $22.8 million for Q4 2025, or $0.42 per share, a decrease from $29.2 million in the prior year period, reflecting reduced spending following pipeline prioritization efforts.
See More
